• Home
  • >
  • Kilitch Drugs India Ltd Financials
https://storage.googleapis.com/assets.cdp.blinkx.in/Blinkx_Website/icons/kilitch-drugs-india-ltd.png Logo

Kilitch Drugs India Ltd Financial Statement

Kilitch Drugs India Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Dec 2023Sep 2023Jun 2023
Revenue33.1632.4932.1
Operating Expense25.7525.7325.89
Net Profit5.54.244.19
Net Profit Margin16.5913.0513.05
Earning Per Share3.482.62.69
EBIDTA7.636.836.82
Effective Tax Rate17.5426.0431.99

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Kilitch Drugs India Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Total Revenue Annual139.6114.2368.52
Operating Expenses Annual122.03103.8763.33
Operating Profit Annual20.4813.287.86
Interest Annual4.921.20.75
Depreciation3.552.471.99
Net Profit Annual10.457.373.77
Tax Annual3.733.41.35

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Kilitch Drugs India Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Cash Flow at the Beginning10.0612.52.8
Cash Flow from Operations2.595.7845.66
Cash Flow from Investing7.92-15.25-37.57
Cash Flow from Financing-0.727.031.61
Cash Flow at the End19.8510.0612.5

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Kilitch Drugs India Ltd Key Ratios

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
PBDIT Margin (%)14.7910.559.9
PBIT Margin (%)12.248.397
PBT Margin (%)9.391.54-0.78
Net PROFIT Margin (%)13.3510.018.8
Return On Networth / Equity (%)5.74.032.41
Return On Networth /Employed(%)10.246.343.51
Return On Assets (%)11.217.514.31
Total Debt / Equity(X)0.110.10.09
Asset Turnover Ratio (%)0.840.750.49

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

Kilitch Drugs India Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Fixed Assets Annual64.2264.5429.96
Total Current Assets Annual126.4114.180.36
Non Current Assets Annual93.1295.74122.81
Total Shareholders Funds Annual151.6139.09127.13
Total Assets Annual219.52209.85203.18

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Kilitch Drugs India Ltd Earning Calls
Dec 2023
EPS beaten by 2.21 %

Open Demat Account

50years
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of May 20, 2024, Kilitch Drugs India Ltd has a market capitalization of 217.45 Cr. Value Research classifies it as a Small-Cap company.

Yes, Kilitch Drugs India Ltd is debt-free with a debt-to-equity ratio of 0.15.

In FY 2023, Kilitch Drugs India Ltd recorded a total revenue of approximately 139.6 Cr marking a significant milestone in the company's financial performance.

Kilitch Drugs India Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.3% and 0.4% annually, respectively..

Kilitch Drugs India Ltd's current PE ratio is 20.81.

Kilitch Drugs India Ltd's ROCE averaged 6.9% from the FY ending March 2021 to 2023, with a median of 6.8%. It peaked at 9.7% in March 2023, reflecting strong capital efficiency over the period..

Kilitch Drugs India Ltd's latest EBIT is Rs. 16.93 Cr, surpassing the average EBIT of Rs. 11.2 Cr over the 5 years..